Poststroke Epilepsy Risk Varies With Antihypertensive Treatment
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 17, 2024 -- For patients with hypertension and ischemic stroke, the risk for poststroke epilepsy (PSE) varies according to antihypertensive treatment, according to a study presented at the annual meeting of the American Epilepsy Society, held from Dec. 6 to 10 in Los Angeles.
Giacomo Evangelista, M.D., Ph.D., from the "G. d'Annunzio" University of Chieti-Pescara in Italy, and colleagues examined the effectiveness of antihypertensive treatment in preventing PSE in a retrospective, observational study. Patients with hypertension and diagnosis of ischemic stroke were retrospectively selected; all participants were followed up for PSE at a mean of 66 months.
The researchers found that 38 of the 528 patients (7.2 percent) developed PSE. The risk for PSE development was higher in association with anterior cerebral artery involvement and cortico-sottocortical lesions. The risk for PSE was lower in patients treated with angiotensin receptor blockers, while incidence was higher for those receiving calcium channel blockers and beta-blockers. No differences were seen for angiotensin-converting enzyme inhibitor use.
"These findings highlight the importance of personalized medicine, particularly in managing blood pressure in stroke patients," co-lead author Fedele Dono, M.D., also from G. d'Annunzio University of Chieti-Pescara, said in a statement. "Further research in more patients is necessary to confirm these findings and explore the underlying mechanisms in more detail."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Prenatal PFAS Exposure Linked to Elevated BP Through Adolescence
MONDAY, June 16, 2025 -- Prenatal exposure to specific perfluoroalkyl and polyfluoroalkyl substances (PFAS) is associated with offspring blood pressure (BP) through age 18 years...
Shorter Leukocyte Telomere Length Linked to Higher Incidence of Age-Related Brain Diseases
THURSDAY, June 12, 2025 -- Individuals with shorter leukocyte telomere length (LTL) have a higher incidence of stroke, dementia, and late-life depression (LLD), individually and...
Talking Therapy Reduces Depression, Anxiety Symptoms in Stroke Survivors
THURSDAY, June 12, 2025 -- For stroke survivors, talking therapy is associated with moderate reductions in depression and large reductions in anxiety symptoms, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.